Chemo Regimen for Ovarian Cancer Mooresville NC

Dose-dense chemotherapy improves survival in women with advanced ovarian cancer, Japanese researchers say. Currently, paclitaxel and carboplatin given every three weeks is considered standard first-line chemotherapy for advanced epithelial ovarian cancer. However, dose-dense weekly treatment with paclitaxel is seen as a way to increase progression-free and overall survival in these patients in Mooresville, according to the new study findings.

David Benjamin Konstandt, MD
(704) 660-3322
Lake Norman Urology 131 Medical Park Dr Suite 305
Mooresville, NC
Specialties
Urology
Gender
Male
Education
Medical School: Wayne State Univ Sch Of Med, Detroit Mi 48201
Graduation Year: 1999

Data Provided by:
Stewart Michael Polsky, MD
(704) 660-3322
131 Medical Park Rd Ste 305
Mooresville, NC
Specialties
Urology
Gender
Male
Education
Medical School: Hahnemann Univ Sch Of Med, Philadelphia Pa 19102
Graduation Year: 1995

Data Provided by:
Michael Raymond Cram, MD
705 Griffith St Ste 205
Davidson, NC
Specialties
Urology
Gender
Male
Education
Medical School: Univ Of Ia Coll Of Med, Iowa City Ia 52242
Graduation Year: 1993

Data Provided by:
R Dale Ensor, MD FACS
(704) 547-1495
16404 Pinwhenny Rd
Cornelius, NC
Gender
Male
Education
Medical School: Ohio State
Graduation Year: 1961

Data Provided by:
John Michael Gazak, MD
(704) 334-3033
16525 Holly Crest Ln Ste 230
Huntersville, NC
Specialties
Urology, Pediatrics
Gender
Male
Languages
Spanish
Education
Medical School: Univ Of Pa Sch Of Med, Philadelphia Pa 19104
Graduation Year: 1974
Hospital
Hospital: Carolinas Med Ctr, Charlotte, Nc; Presbyterian Hospital, Charlotte, Nc
Group Practice: Southeast Children's Urology

Data Provided by:
Robert S Grajewski
(704) 662-9870
131 Medical Park Rd
Mooresville, NC
Specialty
General Surgery, Urology

Data Provided by:
Joel Alan Thurm, MD
704-638-9000 x3268
18529 Dembridge Dr
Davidson, NC
Specialties
Urology
Gender
Male
Education
Medical School: New York Univ Sch Of Med, New York Ny 10016
Graduation Year: 1967

Data Provided by:
Sreeramulu N Nara, MD
PO Box 517
Cornelius, NC
Specialties
Urology
Gender
Male
Education
Medical School: Kurnool Med Coll, Univ Hlth Sci, Kurnool, Ap, India
Graduation Year: 1968

Data Provided by:
Dr.Bernard Taylor
9735 Kincey Avenue, Suite 302
Huntersville, NC
Gender
M
Speciality
Urologist
General Information
Accepting New Patients: Yes
RateMD Rating
5.0, out of 5 based on 2, reviews.

Data Provided by:
Ralph Nelson Vick, MD
(704) 892-2949
16455 Statesville Rd Ste 420
Huntersville, NC
Specialties
Urology
Gender
Male
Education
Medical School: Univ Of Nc At Chapel Hill Sch Of Med, Chapel Hill Nc 27599
Graduation Year: 1997

Data Provided by:
Data Provided by:

Chemo Regimen for Ovarian Cancer

Provided By:

SUNDAY, Sept. 20 (HealthDay News) -- Dose-dense chemotherapy improves survival in women with advanced ovarian cancer, Japanese researchers say.

Currently, paclitaxel and carboplatin given every three weeks is considered standard first-line chemotherapy for advanced epithelial ovarian cancer. However, dose-dense weekly treatment with paclitaxel is seen as a way to increase progression-free and overall survival in these patients, according to the new study findings.

This phase 3 study of 637 women compared the two approaches. The participants had advanced epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.

The 320 patients in the conventional regimen group received six cycles of paclitaxel (180 milligrams per meter squared; three-hour intravenous infusion). The 317 patients in the dose-dense group received paclitaxel (80 milligrams per meter squared; one-hour intravenous infusion) on days one, eight and 15. Both groups received carboplatin on day one of a 21-day cycle.

The patients in the dose-dense group had longer median progression-free survival than those in the standard treatment group (28 months versus 17 months), and longer overall survival at three years (72 percent versus 65 percent). This means that women in the dose-dense group had a 29 percent lower risk of cancer progression and a 25 percent lower risk of death, the authors explained.

Toxicity forced 113 patients in the dose-dense group and 69 patients in the conventional therapy group to stop treatment, the researchers noted. Severe anemia occurred in 214 patients (69 percent) in the dose-dense group and in 137 (44 percent) of the standard therapy group.

The survival benefits seen in the dose-dense group are rare in patients with advanced ovarian cancer, and this regimen offers a new treatment option for women with advanced epithelial ovarian cancer, concluded Dr. Noriyuki Katsumata, of the National Cancer Center Hospital in Tokyo, and colleagues.

The study, published in an upcoming print issue of The Lancet, was released online Sunday to coincide with the European Cancer Organization meeting held Sept. 20 to 24 in Berlin.

"The use of such dose-dense therapy should be decided on an individual basis together with other options for women with advanced-stage ovarian cancer," Dr. Michael A. Bookman, of the Arizona Cancer Center in Tucson, wrote in an accompanying commentary in The Lancet.

More information

The U.S. National Cancer Institute has more about ovarian cancer.

SOURCE: The Lancet, news release, Sept. 19, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com